美國居民不適用 XM 服務。

What other health conditions are weight-loss drugs being tested for?



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>REFILE-FACTBOX-What other health conditions are weight-loss drugs being tested for?</title></head><body>

Adds dropped story tag "FACTBOX" in headline, corrects date to June 24

By Patrick Wingrove

June 24 (Reuters) -Eli Lilly's LLY.N blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's NOVOb.CO rival medicines Ozempic and Wegovy are being studied to see whether they can improve health in other ways.

Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials, Lilly said on Friday.

Below are other conditions obesity treatments are being tested against:


Alcohol Addiction

* A study by the University of Copenhagen's Psychiatric Centre Rigshospitalet is investigating whether semaglutide, sold as Novo's Wegovy and Ozempic, can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity.


Alzheimer's disease

* Novo Nordisk has begun a trial testing semaglutide in patients with early Alzheimer's disease. The study, which will enroll 1,840 patients, could reach primary completion as early as 2025.

Cardiovascular disease

* Eli Lilly is testing tirzepatide, sold as Mounjaro and Zepbound, for patients with heart failure and obesity. Lilly plans to enroll about 700 people in the study, which is expected to be completed by July 2024.

* Researchers at the Chinese University of Hong Kong are testing Novo's semaglutide along with mechanical removal of clots in patients with strokes caused by the blockage of large blood vessels to the brain. The approach will be compared with standard therapy. The mid-stage study aims to recruit about 140 patients.


Chronic kidney disease

* Novo's Ozempic delayed the progression of chronic kidney disease in diabetes patients, cutting the risk of death from that and major cardiac events by 24%. That was, however, below investor expectations.

* Lilly's tirzepatide is being evaluated in a mid-stage study of chronic kidney disease in patients with obesity. Lilly plans to enroll up to 140 participants.

Liver disease

* Novo is testing semaglutide in a late-stage trial of patients with a common type of fatty liver disease called non-alcoholic steatohepatitis (NASH). The study is expected to enroll about 1,200 patients.

* Lilly's tirzepatide helped up to 74% of patients achieve absence of the disease with no worsening of liver scarring at 52 weeks, compared with 13% of patients on placebo, in a mid-stage trial for the fatty liver disease formerly known as NASH and now called metabolic dysfunction-associated steatohepatitis, or MASH.


Neurological disorders

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises. The study aims to recruit about 50 patients and wrap up as early as 2025.


Sleep apnea

* Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials, which included people who use respiratory devices that help keep their airways open while they sleep, as well as people who do notuse such devices.



Reporting by Patrick Wingrove in New York, Sriparna Roy and Christy Santhosh in Bengaluru; Editing by Bill Berkrot, Devika Syamnath and Sriraj Kalluvila

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明